Advertisement

Document › Details
Univercells S.A.. (12/17/20). "Press Release: Univercells Holding Raises €70 Million in Series C Financing". Brussels.
Univercells Holding recently raises €70 million with two rounds of capital increase with new investors. The capital infusion will support the development of GMP facilities and the capacity to foster distributed manufacturing and supply of biologics.
Univercells SA recently completed their Series C second close, bringing the total raised to €70 million. The financing, which was over-subscribed, was led by institutional commitments from international funds including Adjuvant Capital and Belgian public investors SFPI (federal), SRIW (Walloon Region). The second close brings in new international investors the Soros Economic Development Fund and Farallon Capital Management another Fund from Korea Investment Partners (KIP Bio Global Fund) and a new Belgian Fund (TheClubDeal Fund).
Investment proceeds will support establishing GMP capabilities at two sites in Jumet, one dedicated to addressing manufacturing bottlenecks for pandemics, alongside new product and platform development to address key global health needs. The financing will also develop Univercells’ capacity to support distributed manufacturing and supply of biologics.
Created to make biologics available and affordable to all, Univercells is delivering on a global mission from Belgian roots. We are delighted to have further expanded the circle of shareholders to include organizations with new skills and networks to support our scale and success. Since April 2020, Univercells SA is structured as an entrepreneurial holding company with multiple affiliates – Univercells Technologies launched in February 2020 with the support of private equity fund KKR, to expand the supply of manufacturing solutions for gene therapies. A second Univercells company, Exothera, delivers bespoke process optimization and GMP clinical and commercial production of viral vectors in our Belgian sites. More Univercells’ companies are expected to formally launch in 2021.
“After the first Series-C closing of €50M, 3 months ago, I am delighted to complete this financing round with an additional €20M, bringing the funds raised this year to a total of 120€M at the level of our organization. It will help our teams to perform and accelerate the developments to achieve our global health challenges” says Hugues Bultot, CEO of Univercells.
Record changed: 2021-01-07 |
Advertisement

More documents for Univercells (Group)
- [1] Freshfields Brukhaus Deringer. (9/17/20). "Press Release: Freshfields Advises Univercells in Two Successive Equity Raising and Financing"....
- [2] Univercells S.A.. (5/5/20). "Press Release: Launch of Univercells Technologies for Intensified, Automated Technologies"....
- [3] Univercells S.A.. (2/18/20). "Press Release: Univercells Secures up to €50M Investment from KKR Platform to Speed Delivery of Manufacturing Technologies". Brussels....
- [4] Univercells S.A.. (10/3/19). "Press Release: Univercells Boosted by EUR 20m European Financing to Accelerate the Delivery of Its Vaccine Portfolio". Brussels....
- [5] Univercells S.A.. (7/16/18). "Press Release: Univercells Raises €16 Million in Series B Financing Round Led by Global Health Investment Fund". Brussels & New York, NY....
- [6] Univercells S.A.. (6/25/18). "Press Release: Univercells Appoints Christian Borgniet as Chief Operating Officer". Brussels....
- [7] Univercells S.A.. (2/1/18). "News (In the Press): David Shofi Appointed Chief Legal Officer at Univercells". Gosselies....
- [8] Univercells S.A.. (12/15/17). "Press Release: Univercells Secures €3m Series A2 Funding". Gosselies....
- [9] Univercells S.A.. (9/12/17). "Press Release: Univercells Appoints Douglas A. Neugold as Chairman of Its Board of Directors". Brussels....
- [10] Univercells S.A.. (12/15/16). "Press Release: Univercells Receives $12 Million Grant to Develop Breakthrough Vaccine Manufacturing Platform". Brussels....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Advertisement
![Picture [iito] Made Without Love 650x80px](/banner/iito-business-intelligence-20200507-650-080-summer-banner-series-made-without-love.jpg)
» top